Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes ...

Surgical interventions can also be used to manage obesity among children. Laparoscopic sleeve gastrectomy or Roux-en-Y ...

The General Inspectorate of Health Activities (IGAS) has opened a clarification process regarding the marketing of the drug ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, and Okava Pharmaceuticals, Inc.

Vivani Medical, Inc. (NASDAQ: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature ...

Combination therapy with GLP-1 RAs and thiazolidinediones is associated with a reduced risk for mortality in patients with T2D, a study finds.

AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

Background: Obesity is a complex, chronic, stigmatized disease whereby abnormal or excess body fat may impair health or increase the risk of medical complications, and can reduce quality of life and ...

Now, researchers at Thomas Jefferson University have found that combining two other diabetes drugs—dapagliflozin and ...